Claims
- 1. A method for treating the cytopathic destructive effects of a retroviral disease in a host infected with a retrovirus comprising administering to said host an effective amount of an antiviral composition comprising an effective amount of at least one compound selected from the group consisting of 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, and salts and esters thereof, in a pharmaceutically acceptable carrier.
- 2. The method of claim 1 wherein the carrier is suitable for intracellular administration.
- 3. The method of claim 2 wherein the compound is 2',3'-dideoxyinosine triphosphate and the carrier is a liposome.
- 4. The method of claim 1 wherein the carrier is suitable for oral administration and the composition has a pH ranging from 6 to 8.
- 5. The method of claim 1 wherein the carrier is normal saline.
- 6. The method of claim 4 wherein the composition contains an acetate buffer and the pH of said composition is within the range of pH 6.8 to pH 7.2.
- 7. The method of claim 6 wherein the pH of said composition is 7.
- 8. The method of claim 7 wherein the composition includes 25 mg 2',3'-dideoxyadenosine per ml of solution.
- 9. The method of claim 6 wherein the compound is present in an amount of 25 mg compound per ml solution.
- 10. The method of claim 5 wherein the compound is 2',3'-dideoxyadenosine.
- 11. The method of claim 1 wherein the compound is 2',3'-dideoxyinosine.
- 12. The method of claim 1 wherein the compound is 2',3'-dideoxyguanoisine.
- 13. The method of claim 1 wherein the compound is 2',3'-dideoxyadenosine.
- 14. A method of claim 1 wherein the retrovirus is HIV.
- 15. A method of claim 1 wherein the composition administered is dideoxyinosine triphosphate in a liposome.
- 16. A method of claim 1 wherein the composition is an acetate buffered dideoxyadenosine having a pH of 6.8 to 7.2.
- 17. A method of claim 1 wherein the carrier is given in saline and contains 25 mg. nucleoside to each ml. solution.
- 18. A method of claim 17 wherein the nucleoside is dideoxyadenosine.
- 19. A method of claim 1 wherein the composition is given as a continuous intravenous infusion.
- 20. A method of treating HIV infections comprising administering to a host infected with HIV an effective amount of a composition of claim 1.
- 21. A method of claim 1 wherein the route of administration is selected from the group consisting of rectal, nasal, and vaginal routes.
- 22. A method for treating HIV infection comprising administering to a host infected with HIV an effective amount of a composition comprising at least one compound selected from the group consisting of 2',3'-dideoxyinosine, 2',3'-dideoxyguanosine, and 2',3'-dideoxyadenosine, and salts and esters thereof, in a pharmaceutically acceptable carrier.
Parent Case Info
This application is a continuation-in-part of Ser. No. 06/937,925 filed Dec. 4, 1986 now abandoned which is a continuation-in-part of Ser. No. 06/769,016 filed Aug. 26, 1985 now abandoned.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4081534 |
Elion et al. |
Mar 1978 |
|
4434788 |
Nakatsusawa |
Mar 1984 |
|
4577012 |
Tswrushima et al. |
Mar 1986 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
206497 |
Dec 1986 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Prisbe, E. J. et al, Chemical Abstracts, 1985, vol. 103, abstract 123846h. |
Waqar, M. A. et al, J. Cellular Physiology, 121: 402-408, (1984). |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
937925 |
Dec 1986 |
|
Parent |
769016 |
Aug 1985 |
|